TY - JOUR
T1 - Identification of Quantifiable Predictors of Relapse in Patients with Alcohol-Associated Liver Disease
AU - Shen, Nicole T.
AU - Kaplan, Alyson
AU - Fahoum, Khalid
AU - Basu, Elora
AU - Shenoy, Akhil
AU - Wahid, Nabeel
AU - Ivatorov, Amanda
AU - Pisa, Joseph
AU - Salajegheh, Annaheta
AU - Dawod, Enad
AU - Rosenblatt, Russell
AU - Fortune, Brett
AU - Safford, Monika
AU - Brown, Robert S.
N1 - Funding Information:
The authors thank Margie Fernandez-Sloves, Tashi Choney, and Barbara Fishkin for recruitment of patients. The content of this article is solely the responsibility of the authors. Our institutional review board approved the study (protocol #1601016922), and all participants provided written, informed consent. Our study was registered at ClinicalTrials.gov protocol NCT03267069.
Publisher Copyright:
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.
PY - 2021/7
Y1 - 2021/7
N2 - Abstinence in patients with alcohol-associated liver disease (ALD) reduces mortality. Most predictors of relapse are not quantifiable, preventing objective analysis of relapse risk and targeted intervention to improve clinical outcomes. We prospectively enrolled patients with ALD from November 2016 to December 2019 and administered a survey with two previously published scales to assess insight into alcohol-use disorder (Hanil Alcohol Insight Scale [HAIS]) and social support (Community Assessment Inventory Scale [CAIS]). Relapse was assessed using surveys and metabolite testing. Unadjusted and prespecified adjusted regression analyses identified predictors of relapse. We enrolled 81% of eligible patients (n = 136), of whom 58 had follow-up data available at the time of analysis. Over a median follow-up of 1 year (interquartile range: 0.5-1.4), 10 patients relapsed (17%). Patients who relapsed were more likely to continue drinking despite either a diagnosis of liver disease or a decompensating event, and were less likely to have been transplanted (all P < 0.05). In unadjusted regression, the HAIS and the “support inside the home” subcategory of the CAIS were predictive of relapse, with odds ratio (OR) = 0.84 (95% confidence interval 0.72-0.97) and 0.85 (0.74-0.97). In adjusted regression, the HAIS was no longer significant, with adjusted OR = 0.70 (0.49-1.00, P = 0.05), whereas the “support inside the home’ subcategory of CAIS remained significant, with adjusted OR = 0.69 (0.51-0.92, P = 0.01). Conclusions: Risk factors for relapse in patients with ALD were identified and quantified prospectively, suggesting opportunities to objectively identify patients at risk for relapse as well as to intervene to prevent relapse.
AB - Abstinence in patients with alcohol-associated liver disease (ALD) reduces mortality. Most predictors of relapse are not quantifiable, preventing objective analysis of relapse risk and targeted intervention to improve clinical outcomes. We prospectively enrolled patients with ALD from November 2016 to December 2019 and administered a survey with two previously published scales to assess insight into alcohol-use disorder (Hanil Alcohol Insight Scale [HAIS]) and social support (Community Assessment Inventory Scale [CAIS]). Relapse was assessed using surveys and metabolite testing. Unadjusted and prespecified adjusted regression analyses identified predictors of relapse. We enrolled 81% of eligible patients (n = 136), of whom 58 had follow-up data available at the time of analysis. Over a median follow-up of 1 year (interquartile range: 0.5-1.4), 10 patients relapsed (17%). Patients who relapsed were more likely to continue drinking despite either a diagnosis of liver disease or a decompensating event, and were less likely to have been transplanted (all P < 0.05). In unadjusted regression, the HAIS and the “support inside the home” subcategory of the CAIS were predictive of relapse, with odds ratio (OR) = 0.84 (95% confidence interval 0.72-0.97) and 0.85 (0.74-0.97). In adjusted regression, the HAIS was no longer significant, with adjusted OR = 0.70 (0.49-1.00, P = 0.05), whereas the “support inside the home’ subcategory of CAIS remained significant, with adjusted OR = 0.69 (0.51-0.92, P = 0.01). Conclusions: Risk factors for relapse in patients with ALD were identified and quantified prospectively, suggesting opportunities to objectively identify patients at risk for relapse as well as to intervene to prevent relapse.
UR - http://www.scopus.com/inward/record.url?scp=85109725982&partnerID=8YFLogxK
U2 - 10.1002/hep4.1704
DO - 10.1002/hep4.1704
M3 - Article
AN - SCOPUS:85109725982
VL - 5
SP - 1156
EP - 1164
JO - Hepatology Communications
JF - Hepatology Communications
SN - 2471-254X
IS - 7
ER -